Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 368
- Registration Number
- NCT02760433
- Locations
- 🇧🇷
CEDOES - Diagnóstico e Pesquisa, Vitória, EspÃrito Santo, Brazil
🇧🇷CMiP - Centro Mineiro de Pesquisa, Juiz de Fora, Minas Gerais, Brazil
🇧🇷Hospital Bruno Born, Lajeado, Rio Grande Do Sul, Brazil
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- R-Pharm International, LLC
- Target Recruit Count
- 428
- Registration Number
- NCT02760368
- Locations
- 🇷🇺
SBEI HPE "Rostov State Medical University" of Ministry of Health of the Russian Federation, Rostov, Rostovskaya Oblast, Russian Federation
🇷🇺SBHI of the Republic of Karelia "Republican Hospital named after V.A. Baranov", Petrozavodsk, Republic Of Karelia, Russian Federation
🇷🇺SBHI of Stavropol Region "Stavropol Regional Clinical Hospital", Stavropol', Stavropol Region, Russian Federation
© Copyright 2024. All Rights Reserved by MedPath